Lupin launches generic diabetes drug in the US

NEW DELHI: Drug maker Lupin Pharmaceuticals Inc today launched metformin, its generic copy of diabetes drug Glumetza, in the US market. A First-to-File (FTF) product, the company will be priced 15-20% lower and enjoy 180 days of marketing exclusivity by the US Food and Drug Administration (FDA).

“Lupin Pharmaceuticals Inc. has launched its metformin HCl ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc’s Glumetza HCl ER Tablets, 500 mg and 1000 mg,” stated the company in a release. “It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus,” it added.

Lupin has launched 10 products in the US this fiscal year and has received approvals for 21 from the FDA. The drug maker has 35 FTF products.